Register for our free email digests:
Ablynx NV
Division of Sanofi
www.ablynx.com
Latest From Ablynx NV
2019 Drug Launches: New Specialty And Rare Disease Blockbusters Take Shape
Novartis' Zolgensma and Pfizer's Vyndaqel were two of the early commercial standouts in 2019, on a likely blockbuster trajectory, while AbbVie's Skyrizi is poised to be fierce competitor in psoriasis.
Investigating Big Pharma Licensing Trends
AstraZeneca emerged as big pharma’s most active dealmaker over the 2014-2018 period, thanks to a combined surge in both in-licensing and out-licensing agreements.
AstraZeneca’s Outlicensing Tactics Make It Top Dealmaker
Datamonitor report highlights big pharma’s licensing trends from last five years, and finds UK firm top on numbers of deals, but Merck & Co put up most money.
Finance Watch: Here Come The IPOs Again As Bellus Raises $70m And Vir Joins The Queue
Public Company Edition: Bellus launched the first biopharma IPO in the US since mid-July and Vir Biotechnology, run by former Biogen CEO George Scangos, wants to raise $100m. Also, Turning Point's $202.5m offering and Zafgen's strategic review.
Company Information
- Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Cancer
- Immune Disorders
- Inflammation
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Benelux
-
Belgium
-
Belgium
-
Benelux
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Sanofi
- Senior Management
-
Edwin Moses, PhD, CEO
Wim Ottevaere, CFO
Markus Ewert, PhD, CBO
Robert K Zeldin, MD, CMO
Heylen Johan, Chief Commerical Officer
Robert Friesen, PhD, CSO - Contact Info
-
Ablynx NV
Phone: (32) 9 262 00 00
Technologiepark 21
Ghent/Zwijnaarde, 9052
Belgium
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice